FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068014745> ?p ?o ?g. }

• W2068014745 endingPage "124" @default.
• W2068014745 startingPage "117" @default.
• W2068014745 abstract "Vascular endothelial growth factor promotes angiogenesis, an important mediator of growth and metastasis in human breast cancer. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, is under investigation as an anti-angiogenic agent. This phase I/II trial evaluated the safety and efficacy of bevacizumab in patients with previously treated metastatic breast cancer. Seventy-five patients were treated with escalating doses of bevacizumab ranging from 3 mg/kg to 20 mg/kg administered intravenously every other week. Tumor response was assessed before the sixth (70 days) and 12th (154 days) doses. Safety was evaluated during every cycle. Eighteen patients were treated at 3 mg/kg, 41 at 10 mg/kg, and 16 at 20 mg/kg. Four patients discontinued study treatment because of an adverse event. Hypertension was reported as an adverse event in 17 patients (22%). The overall response rate was 9.3% (confirmed response rate, 6.7%). The median duration of confirmed response was 5.5 months (range, 2.3 to 13.7 months). At the final tumor assessment on day 154, 12 of 75 patients (16%) had stable disease or an ongoing response. The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable. These data support the initiation of trials in metastatic breast cancer combining bevacizumab with chemotherapy." @default.
• W2068014745 created "2016-06-24" @default.
• W2068014745 creator A5003170725 @default.
• W2068014745 creator A5012490417 @default.
• W2068014745 creator A5043219897 @default.
• W2068014745 creator A5060799552 @default.
• W2068014745 creator A5066769011 @default.
• W2068014745 creator A5067390775 @default.
• W2068014745 creator A5068666503 @default.
• W2068014745 creator A5078945340 @default.
• W2068014745 date "2003-10-01" @default.
• W2068014745 modified "2023-09-26" @default.
• W2068014745 title "A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer" @default.
• W2068014745 cites W103956845 @default.
• W2068014745 cites W1592045168 @default.
• W2068014745 cites W1837651204 @default.
• W2068014745 cites W1886850372 @default.
• W2068014745 cites W1969328947 @default.
• W2068014745 cites W1978139448 @default.
• W2068014745 cites W1984758613 @default.
• W2068014745 cites W2009240587 @default.
• W2068014745 cites W2037761545 @default.
• W2068014745 cites W2087523741 @default.
• W2068014745 cites W2087933507 @default.
• W2068014745 cites W2093498435 @default.
• W2068014745 cites W2144048908 @default.
• W2068014745 cites W2145224595 @default.
• W2068014745 cites W2154200023 @default.
• W2068014745 cites W2155090369 @default.
• W2068014745 cites W2167528781 @default.
• W2068014745 cites W2167973059 @default.
• W2068014745 cites W2171998177 @default.
• W2068014745 cites W2295734057 @default.
• W2068014745 doi "https://doi.org/10.1053/j.seminoncol.2003.08.013" @default.
• W2068014745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14613032" @default.
• W2068014745 hasPublicationYear "2003" @default.
• W2068014745 type Work @default.
• W2068014745 sameAs 2068014745 @default.
• W2068014745 citedByCount "439" @default.
• W2068014745 countsByYear W20680147452012 @default.
• W2068014745 countsByYear W20680147452013 @default.
• W2068014745 countsByYear W20680147452014 @default.
• W2068014745 countsByYear W20680147452015 @default.
• W2068014745 countsByYear W20680147452016 @default.
• W2068014745 countsByYear W20680147452017 @default.
• W2068014745 countsByYear W20680147452018 @default.
• W2068014745 countsByYear W20680147452019 @default.
• W2068014745 countsByYear W20680147452020 @default.
• W2068014745 countsByYear W20680147452021 @default.
• W2068014745 countsByYear W20680147452022 @default.
• W2068014745 countsByYear W20680147452023 @default.
• W2068014745 crossrefType "journal-article" @default.
• W2068014745 hasAuthorship W2068014745A5003170725 @default.
• W2068014745 hasAuthorship W2068014745A5012490417 @default.
• W2068014745 hasAuthorship W2068014745A5043219897 @default.
• W2068014745 hasAuthorship W2068014745A5060799552 @default.
• W2068014745 hasAuthorship W2068014745A5066769011 @default.
• W2068014745 hasAuthorship W2068014745A5067390775 @default.
• W2068014745 hasAuthorship W2068014745A5068666503 @default.
• W2068014745 hasAuthorship W2068014745A5078945340 @default.
• W2068014745 hasConcept C121608353 @default.
• W2068014745 hasConcept C126322002 @default.
• W2068014745 hasConcept C141071460 @default.
• W2068014745 hasConcept C143998085 @default.
• W2068014745 hasConcept C167734588 @default.
• W2068014745 hasConcept C197934379 @default.
• W2068014745 hasConcept C2775930923 @default.
• W2068014745 hasConcept C2776694085 @default.
• W2068014745 hasConcept C2777025900 @default.
• W2068014745 hasConcept C2777802072 @default.
• W2068014745 hasConcept C2779013556 @default.
• W2068014745 hasConcept C2780394083 @default.
• W2068014745 hasConcept C31760486 @default.
• W2068014745 hasConcept C530470458 @default.
• W2068014745 hasConcept C71924100 @default.
• W2068014745 hasConcept C90924648 @default.
• W2068014745 hasConceptScore W2068014745C121608353 @default.
• W2068014745 hasConceptScore W2068014745C126322002 @default.
• W2068014745 hasConceptScore W2068014745C141071460 @default.
• W2068014745 hasConceptScore W2068014745C143998085 @default.
• W2068014745 hasConceptScore W2068014745C167734588 @default.
• W2068014745 hasConceptScore W2068014745C197934379 @default.
• W2068014745 hasConceptScore W2068014745C2775930923 @default.
• W2068014745 hasConceptScore W2068014745C2776694085 @default.
• W2068014745 hasConceptScore W2068014745C2777025900 @default.
• W2068014745 hasConceptScore W2068014745C2777802072 @default.
• W2068014745 hasConceptScore W2068014745C2779013556 @default.
• W2068014745 hasConceptScore W2068014745C2780394083 @default.
• W2068014745 hasConceptScore W2068014745C31760486 @default.
• W2068014745 hasConceptScore W2068014745C530470458 @default.
• W2068014745 hasConceptScore W2068014745C71924100 @default.
• W2068014745 hasConceptScore W2068014745C90924648 @default.
• W2068014745 hasLocation W20680147451 @default.
• W2068014745 hasLocation W20680147452 @default.
• W2068014745 hasOpenAccess W2068014745 @default.
• W2068014745 hasPrimaryLocation W20680147451 @default.
• W2068014745 hasRelatedWork W144521535 @default.
• W2068014745 hasRelatedWork W2023654245 @default.

• next